Actinium Pharmaceuticals, Inc.ATNMNYSE
Loading
Year-over-year free cash flow growth rate
Percentile
P36
Within normal range
vs 2Y Ago
-0.9x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -17.30% |
| Q2 2025 | 28.81% |
| Q1 2025 | -31.70% |
| Q4 2024 | 51.97% |
| Q3 2024 | -50.21% |
| Q2 2024 | -7.95% |
| Q1 2024 | 1.40% |
| Q4 2023 | 32.86% |
| Q3 2023 | 18.52% |
| Q2 2023 | 9.65% |
| Q1 2023 | -94.42% |
| Q4 2022 | -34.66% |
| Q3 2022 | -120.93% |
| Q2 2022 | 577.68% |
| Q1 2022 | -14.57% |
| Q4 2021 | 10.68% |
| Q3 2021 | -21.77% |
| Q2 2021 | 17.73% |
| Q1 2021 | 13.18% |
| Q4 2020 | -30.01% |
| Q3 2020 | -10.88% |
| Q2 2020 | 22.94% |
| Q1 2020 | -16.73% |
| Q4 2019 | 10.43% |
| Q3 2019 | -4.24% |
| Q2 2019 | 3.06% |
| Q1 2019 | -28.93% |
| Q4 2018 | 35.60% |
| Q3 2018 | -57.72% |
| Q2 2018 | 22.60% |
| Q1 2018 | -72.45% |
| Q4 2017 | 46.06% |
| Q3 2017 | 17.79% |
| Q2 2017 | -32.79% |
| Q1 2017 | -26.42% |
| Q4 2016 | 23.57% |
| Q3 2016 | 10.65% |
| Q2 2016 | -30.34% |
| Q1 2016 | -20.05% |
| Q4 2015 | -13.04% |